Are there any interactions between fluconazole (antifungal) and azithromycin (antibiotic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug Interactions Between Fluconazole and Azithromycin

There is no clinically significant pharmacokinetic interaction between fluconazole and azithromycin, and these medications can be safely co-administered without dose adjustment. 1

Evidence from FDA Drug Labels

The FDA label for fluconazole explicitly addresses this combination, stating that an open-label, randomized, three-way crossover study in 18 healthy subjects found no significant pharmacokinetic interaction between fluconazole and azithromycin when a single 800 mg oral dose of fluconazole was given with a single 1200 mg oral dose of azithromycin. 1

Similarly, the azithromycin FDA label confirms that when used in therapeutic doses, azithromycin had only a modest effect on fluconazole pharmacokinetics, and no dosage adjustment of either drug is recommended when co-administered. 2

Supporting Research Evidence

A dedicated pharmacokinetic study in healthy volunteers specifically evaluated this combination and confirmed that azithromycin does not alter the bioavailability of fluconazole, and fluconazole does not significantly alter azithromycin parameters. 3

Important QTc Prolongation Consideration

Both medications can independently prolong the QTc interval, which represents the primary clinical concern when using them together. 4

Risk Factors Requiring Monitoring:

  • Pre-existing QTc prolongation or cardiac conduction abnormalities 4
  • Concurrent use of other QT-prolonging medications 4
  • Electrolyte abnormalities (hypokalemia, hypomagnesemia) 4
  • High-dose fluconazole (≥400 mg daily) increases this risk 4, 5

Clinical Management Algorithm:

  • Baseline ECG assessment may be considered in high-risk patients (those with cardiac history, electrolyte disturbances, or taking multiple QT-prolonging drugs) 4
  • Monitor and correct electrolytes before initiating therapy, particularly potassium and magnesium 4
  • Avoid adding a third QT-prolonging agent to this combination 4
  • Use caution with azithromycin 1000 mg single doses, as higher doses are associated with more gastrointestinal side effects and potentially greater QTc effects 4

Guideline Context for Combined Use

The combination of antibiotics and antifungals is commonly employed in clinical practice for mixed or suspected polymicrobial infections without safety concerns beyond the QTc consideration. 6 Guidelines for travelers' diarrhea note that azithromycin has good tolerability overall, though sustained ventricular tachycardia has been observed in patients with prolonged QTc. 4

Common Pitfalls to Avoid

  • Do not assume all azole-macrolide combinations are equivalent: Clarithromycin and erythromycin have significantly more CYP3A4 interactions than azithromycin, making azithromycin the preferred macrolide when combined with fluconazole. 4
  • Do not overlook the patient's complete medication list: Fluconazole is a moderate CYP3A4 inhibitor and can increase levels of other drugs metabolized through this pathway (statins, calcium channel blockers, benzodiazepines). 1, 7
  • Do not use fluconazole empirically in Southeast/South Asia for diarrheal illness if fluoroquinolone resistance is a concern, though this is unrelated to the azithromycin interaction. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fluconazole, Dextromethorphan, and Guaifenesin Interactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safe Combination of Cefpodoxime, Azithromycin, and Fluconazole

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.